Compounds targeting signaling pathways upregulated in T-ALL subtypes, including NOTCH, mTOR/PI3K, and JAK/STAT, have shown promise, and some are in current clinical trials [2–4]. The gene discussed is MTOR; the disease is acute lymphoblastic leukemia.